Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib

Haematologica

Volumn 93, Issue 3, 2008, Pages 451-454

  Anargyrou, Konstantinos ^a,b   Terpos, Evangelos ^a   Vassilakopoulos, Theodoros P ^b   Pouli, Anastasia ^c   Sachanas, Sotirios ^b   Tzenou, Tatiana ^b   Masouridis, Stavroula ^b   Christoulas, Dimitrios ^a   Angelopoulou, Maria K ^b   Dimitriadou, Evangelia M ^b   Kalpadakis, Christina ^b   Tsionos, Konstantinos ^a   Panayiotidis, Panayiotis ^b   Dimopoulos, Meletios A ^b   Pangalis, Gerassimos A ^b   Kyrtsonis, Marie Christine ^b  

^a 251 GENERAL AIR FORCE HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c SAINT SAVVAS HOSPITAL   (Greece)

Author keywords

Bortezomib; Myeloma; Serum Ang 1 Ang 2 ratio; Serum angiopoietins

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; BORTEZOMIB; DEXAMETHASONE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANTINEOPLASTIC AGENTS; BONE MARROW; BORONIC ACIDS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PROTEASE INHIBITORS; PYRAZINES; RECEPTOR, TIE-2; SALVAGE THERAPY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 40849146069     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11852     Document Type: Article

References (20)

1. Rajkumar SV, Leong T, Roche PC, Fonseca R, Dispenzieri A, Lacy MQ, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000;6:3111-6.
2. Sezer O, Niemöller K, Eucker J, Jakob C, Kaufmann O, Zavrski I, et al. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol 2000;79:574-77.
3. Vacca A, Ribatti D, Roccaro AM, Frigeri A, Dammacco F. Bone marrow angiogenesis in patients with active multiple myeloma. Semin Oncol 28;543-50.
4. Molina JR, Rajkumar SV. Bone marrow angiogenesis in multiple myeloma: closing in on the loop. Haematologica 2003;88:122-24.
5. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994-8.
6. Uneda S, Matsuno F, Sonoki T, Tniguchi I, Kawano F, Hata H. Expression of vascular endothelial factor and angiopoietin-2 in myeloma cells. Haematologica 2003;88:113-5.
7. Giulani N, Colla S, Lazzaretti M, Sala R, Roti G, Mancini C, et al. Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. Blood 2003;102:638-45.
8. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, et al. Isolation of angiopoietin-1, a ligant for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996;87:1161-9.
9. Scharpfenecker M, Fiedler U, Reiss Y, Augustin HG. The Tie-2 ligant angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J of Cell Science 2005;118:771-80.
10. Pangalis GA, Kyrtsonis MC, Vassilakopoulos TP, Dimopoulou MN, Siakantaris MP, Emmanouilides C, et al. Immunotherapeutic and immunoregulatory drugs in hematologic malignancies. Curr Top Med Chem 2006;6:1657-86.
11. Quartarone E, Alonci A, Allegra A, Bellomo G, Calabro L, D' Angelo A, et al. Differential levels of soluble angiopoietin-2 and Tie-2 in patients with haematological malignancies. Eur J Haematol 2006;77:480-5.
12. Alexandrakis MG, Passam FH, Sfiridaki A, Kyriakou DS, Petreli E, Roussou P. Elevated serum angiogenin in multiple myeloma. Hematol J 2003;4:454-5.
13. Anagnostopoulos A, Eleftherakis-Papaiakovou V, Zervas K, Kastritis E, Tsionos K, Bamias A, et al. Serum concentrations of angiogenic cytokines in Waldenstrom's macroglobulinaemia: the ratio of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity. Br J Haematol 2007; 23:560-8.
14. Vacca A, Scavelli C, Montefusco V, Di Pietro G, Neri A, Mattioli M, et al. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol 2005;23:5334-46.
15. Schliemann C, Bieker R, Padro T, Kessler T, Hintelmann H, Buchner T, et al. Expression of angiopoietins and their receptor Tie2 in the bone marrow of patients with acute myeloid leukemia. Haematologica 2006;91:1203-11.
16. Sfiligoi C, de Luca A, Cascone I, Sorbello V, Fuso L, Ponzone R, et al. Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival. Int J Cancer 2003;103:466-74.
17. Etoh T, Inoue H, Tanaka S, Barnard GF, Kitano S, Mori M. Angiopoietin-2 is related to tumour angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. Cancer Res 2001;61:2145-53.
18. Oliner J, Min H, Leal J, Yu D, Rao S, You E, et al. Suppression of angiogenesis and tumour growth by selective inhibition of angiopoietin-2. Cancer Cell 2004;6:507-16.
19. Li JJ, Huang YQ, Basch R, Karpatkin S. Thrombin induces the release of angiopoietin-1 from platelets. Thromb Haemost 2001;85:204-6.
20. Roccaro AM, Hideshima T, Raje N, Kumar S, Ishitsuka K, Yasui H, et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 2006;66:184-91.